The regulation of complementary and alternative medicines in South Africa is a complex and evolving issue, with a long history of legal battles and ongoing challenges. In this article, we delve into the intricacies of this regulatory saga, exploring the legal framework, the current state of affairs, and the gaps that remain. We also discuss the future direction of this regulatory process and its implications for the healthcare industry.
The Legal Framework
The Medicines and Related Substances Act of 1965 laid the foundation for the regulation of medicines in South Africa. This act introduced the concept of a 'call-up notice', which is a declaration that a category or class of medicine is subject to registration. The act also established the South African Health Products Regulatory Authority (Sahpra) as the body responsible for regulating medicines.
Complementary Medicines and Their Regulation
Complementary medicines, which include homoeopathic medicines and health supplements, have been a contentious issue in South Africa. The act has been amended to accommodate this wider range of medicines, and a separate website is dedicated to Category D medicines, also known as complementary medicines.
The General Regulations issued in terms of the Medicines Act provide a definition of complementary medicines, which includes health supplements and medicines used in accordance with a 'discipline as determined by the Authority'. This definition has two components: the nature of the substance included in the complementary medicine and the claims made in relation to that medicine.
The Regulatory Process
Since 2013, the intention has been to progressively bring all complementary medicines under effective regulation, using a risk-based approach to identify those that require registration and full assessment of safety, efficacy, and quality data. However, no complementary medicines have yet been registered, and the initial 'call-up notices' have been repealed.
Gaps in the System
The regulatory scheme for complementary medicines remains incomplete. A risk-based 'call-up' process still needs to commence, and moving from an attestation process to confirmation that every manufacturer has met current Good Manufacturing Practice standards is still necessary.
Future Direction
The future direction of the regulatory process is uncertain, but it is clear that the gaps in the system need to be addressed. The regulation of African traditional medicines, which are not currently captured by the definition of Category D medicines, is a particular gap that has never been adequately addressed.
In conclusion, the regulation of complementary and alternative medicines in South Africa is a complex and evolving issue, with a long history of legal battles and ongoing challenges. The regulatory scheme remains incomplete, and the gaps in the system need to be addressed to ensure the safety and efficacy of these medicines.
